thymine has been researched along with Local Neoplasm Recurrence in 18 studies
Excerpt | Relevance | Reference |
---|---|---|
"Trifluridine/tipiracil (TFTD), with or without bevacizumab (Bev), and regorafenib are salvage chemotherapy options for metastatic colorectal cancer (mCRC)." | 8.12 | Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer. ( Boku, N; Hirano, H; Iwasa, S; Okita, N; Oshima, K; Shoji, H; Takashima, A, 2022) |
"This study aimed to clarify the tolerability of a trifluridine/tipiracil combination tablet (TAS-102) in patients with advanced or recurrent colorectal cancer over 75 years of age." | 7.91 | Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer. ( Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2019) |
"Elucidating the factors influencing severe neutropenia could aid in earlier management of neutropenia during oral trifluridine-tipiracil (TAS-102) chemotherapy in advanced and recurrent colorectal cancer (CRC)." | 7.88 | Risk factors contributing to the development of neutropenia in patients receiving oral trifluridine-tipiracil (TAS-102) chemotherapy for advanced/recurrent colorectal cancer. ( Ikeda, Y; Iwai, M; Kawachi, S; Kimura, M; Mitsuoka, M; Usami, E; Yasue, F; Yoshimura, T, 2018) |
"TAS-102 (trifluridine-tipiracil) has shown a significant overall survival benefit compared with placebo in patients with chemorefractory metastatic colorectal cancer." | 5.34 | TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. ( Krogh, M; Möller, S; Petersen, LN; Pfeiffer, P; Poulsen, LØ; Qvortrup, C; Thomsen, KG; Winther, SB; Yilmaz, M; Zitnjak, D, 2020) |
"For patients with refractory metastatic colorectal cancer (mCRC) treatment with Trifluridine/Tipiracil, also known as TAS-102, improves overall survival." | 4.12 | Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer. ( Ananda, S; Banks, S; Dunn, C; Gard, G; Gately, L; Gibbs, P; Jalali, A; Jennens, R; Khattak, A; Kosmider, S; Lee, B; Lee, M; Lim, L; Loft, M; McKendrick, J; Shapiro, JD; Tie, J; Wong, HL; Wong, R; Yeung, JM, 2022) |
"Trifluridine/tipiracil (TFTD), with or without bevacizumab (Bev), and regorafenib are salvage chemotherapy options for metastatic colorectal cancer (mCRC)." | 4.12 | Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer. ( Boku, N; Hirano, H; Iwasa, S; Okita, N; Oshima, K; Shoji, H; Takashima, A, 2022) |
"Trifluridine/tipiracil (TAS-102) is an important chemotherapeutic agent recommended by the Japanese guidelines as third- or fourth-line treatment for colorectal cancer." | 4.02 | [Two Cases of Metastatic Colorectal Cancer Treated with TAS-102 plus Bevacizumab]. ( Amagasa, H; Ami, K; Ando, M; Fukuda, A; Gan, S; Ganno, H; Iida, S; Imai, K; Kajiyama, D; Kawaguchi, M; Maeda, F; Motoyama, K; Okano, Y; Tokitou, F; Yamada, A, 2021) |
"Trifluridine/tipiracil (FTD/TPI) improves the overall survival (OS) of metastatic colorectal cancer (mCRC) patients." | 3.96 | Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: a retrospective study. ( Hata, T; Kagawa, Y; Kato, T; Katsura, Y; Kawai, K; Masuzawa, T; Mori, R; Murakami, K; Murata, K; Naito, A; Nose, Y; Ohmura, Y; Sakamoto, T; Takeda, Y; Takeno, A, 2020) |
"This study aimed to clarify the tolerability of a trifluridine/tipiracil combination tablet (TAS-102) in patients with advanced or recurrent colorectal cancer over 75 years of age." | 3.91 | Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer. ( Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2019) |
"Elucidating the factors influencing severe neutropenia could aid in earlier management of neutropenia during oral trifluridine-tipiracil (TAS-102) chemotherapy in advanced and recurrent colorectal cancer (CRC)." | 3.88 | Risk factors contributing to the development of neutropenia in patients receiving oral trifluridine-tipiracil (TAS-102) chemotherapy for advanced/recurrent colorectal cancer. ( Ikeda, Y; Iwai, M; Kawachi, S; Kimura, M; Mitsuoka, M; Usami, E; Yasue, F; Yoshimura, T, 2018) |
"The effect of oral trifluridine-tipiracil (TAS-102)-induced neutropenia on survival of patients with advanced/recurrent colorectal cancer was investigated." | 3.85 | Severe neutropenia: a prognosticator in patients with advanced/recurrent colorectal cancer ( Iwai, M; Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2017) |
" Adverse events to TAS-102 monotherapy were observed in 22 out of 23 cases (95." | 1.43 | Safety of an oral anticancer agent (trifluridine/tipiracil combination tablet) in patients with advanced and recurrent colorectal cancer. ( Asano, H; Go, M; Ito, D; Iwai, M; Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2016) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (5.56) | 29.6817 |
2010's | 9 (50.00) | 24.3611 |
2020's | 8 (44.44) | 2.80 |
Authors | Studies |
---|---|
Jalali, A | 1 |
Gard, G | 1 |
Banks, S | 1 |
Dunn, C | 1 |
Wong, HL | 1 |
Wong, R | 1 |
Lee, M | 1 |
Gately, L | 1 |
Loft, M | 1 |
Shapiro, JD | 1 |
Kosmider, S | 1 |
Tie, J | 1 |
Ananda, S | 1 |
Yeung, JM | 1 |
Jennens, R | 1 |
Lee, B | 1 |
McKendrick, J | 1 |
Lim, L | 1 |
Khattak, A | 1 |
Gibbs, P | 1 |
Oshima, K | 1 |
Hirano, H | 1 |
Shoji, H | 1 |
Iwasa, S | 1 |
Okita, N | 1 |
Takashima, A | 1 |
Boku, N | 1 |
Pfeiffer, P | 1 |
Yilmaz, M | 1 |
Möller, S | 1 |
Zitnjak, D | 1 |
Krogh, M | 1 |
Petersen, LN | 1 |
Poulsen, LØ | 1 |
Winther, SB | 1 |
Thomsen, KG | 1 |
Qvortrup, C | 1 |
Nose, Y | 1 |
Kagawa, Y | 1 |
Hata, T | 1 |
Mori, R | 1 |
Kawai, K | 1 |
Naito, A | 2 |
Sakamoto, T | 1 |
Murakami, K | 1 |
Katsura, Y | 1 |
Ohmura, Y | 1 |
Masuzawa, T | 1 |
Takeno, A | 1 |
Takeda, Y | 1 |
Kato, T | 2 |
Murata, K | 1 |
Hamada, S | 1 |
Komatsu, S | 1 |
Shibata, R | 1 |
Konishi, T | 1 |
Matsubara, D | 1 |
Soga, K | 1 |
Shimomura, K | 1 |
Ikeda, J | 1 |
Taniguchi, F | 1 |
Shioaki, Y | 1 |
Iwamoto, K | 1 |
Ohtsuka, M | 1 |
Imasato, M | 1 |
Inui, M | 1 |
Zenitani, S | 1 |
Wada, R | 1 |
Nakahara, Y | 1 |
Mikamori, M | 1 |
Furukawa, K | 1 |
Moon, J | 1 |
Asaoka, T | 1 |
Kishi, K | 1 |
Akamatsu, H | 1 |
Maeda, F | 1 |
Gan, S | 1 |
Yamada, A | 1 |
Kajiyama, D | 1 |
Tokitou, F | 1 |
Kawaguchi, M | 1 |
Amagasa, H | 1 |
Motoyama, K | 1 |
Ganno, H | 1 |
Imai, K | 1 |
Ami, K | 1 |
Iida, S | 1 |
Fukuda, A | 1 |
Ando, M | 1 |
Okano, Y | 1 |
Taniguchi, H | 1 |
Nakamura, Y | 1 |
Kotani, D | 1 |
Yukami, H | 1 |
Mishima, S | 1 |
Sawada, K | 1 |
Shirasu, H | 1 |
Ebi, H | 1 |
Yamanaka, T | 1 |
Aleshin, A | 1 |
Billings, PR | 1 |
Rabinowitz, M | 1 |
Oki, E | 1 |
Takemasa, I | 1 |
Mori, M | 1 |
Yoshino, T | 1 |
Kimura, M | 4 |
Usami, E | 4 |
Iwai, M | 3 |
Teramachi, H | 3 |
Yoshimura, T | 4 |
Arnold, D | 1 |
Prager, GW | 1 |
Quintela, A | 1 |
Stein, A | 1 |
Moreno Vera, S | 1 |
Mounedji, N | 1 |
Taieb, J | 1 |
Yasue, F | 1 |
Kawachi, S | 1 |
Mitsuoka, M | 1 |
Ikeda, Y | 1 |
Goldberg, R | 1 |
Go, M | 1 |
Ito, D | 1 |
Asano, H | 1 |
Saito, T | 1 |
Mitomi, H | 1 |
Izumi, H | 1 |
Suehara, Y | 1 |
Okubo, T | 1 |
Torigoe, T | 1 |
Takagi, T | 1 |
Kaneko, K | 1 |
Sato, K | 1 |
Matsumoto, T | 1 |
Yao, T | 1 |
Eshghyar, N | 1 |
Nikbin, B | 1 |
Amirzargar, A | 1 |
Dehghani Nazhvani, A | 1 |
Shakiba, Y | 1 |
Kämmerer, PW | 1 |
Koch, FP | 1 |
Schiegnitz, E | 1 |
Kumar, VV | 1 |
Berres, M | 1 |
Toyoshima, T | 1 |
Al-Nawas, B | 1 |
Brieger, J | 1 |
Vashist, YK | 1 |
Blessmann, M | 1 |
Trump, F | 1 |
Kalinin, V | 1 |
Kutup, A | 1 |
Schneider, C | 1 |
Gawad, K | 1 |
Kaifi, JT | 1 |
Schmelzle, R | 1 |
Izbicki, JR | 1 |
Yekebas, EF | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Randomized, Controlled Phase II Clinical Trial of Fruquintinib Combined With Raltitrexed Versus Fruquintinib Monotherapy in Patients With Advanced Colorectal Cancer Who Had Failed Second-line or Above Standard Chemotherapy[NCT04582981] | Phase 2 | 136 participants (Anticipated) | Interventional | 2020-09-28 | Recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 review available for thymine and Local Neoplasm Recurrence
Article | Year |
---|---|
Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review.
Topics: Colorectal Neoplasms; Disease Progression; Drug Combinations; Drugs, Investigational; Humans; Neopla | 2018 |
2 trials available for thymine and Local Neoplasm Recurrence
Article | Year |
---|---|
TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combin | 2020 |
CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Circulating Tu | 2021 |
15 other studies available for thymine and Local Neoplasm Recurrence
Article | Year |
---|---|
Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Colonic Neoplasms; Colorectal Neoplasms; | 2022 |
Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Humans; Neoplasm | 2022 |
Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorec | 2020 |
[Long-Term Survivor with Recurrent Gastric Cancer Using Trifluridine/Tipiracil as a Late-Line Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Neo | 2020 |
[Case Series of the TAS-102 plus Bevacizumab(Bev)Combination Therapy in Unresectable Advanced Colorectal Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations | 2020 |
[Two Cases of Metastatic Colorectal Cancer Treated with TAS-102 plus Bevacizumab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations | 2021 |
Severe neutropenia: a prognosticator in patients with advanced/recurrent colorectal cancer
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2017 |
Risk factors contributing to the development of neutropenia in patients receiving oral trifluridine-tipiracil (TAS-102) chemotherapy for advanced/recurrent colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Creatinine; Drug Combinations; Female; Humans; | 2018 |
Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Co | 2019 |
Emerging phase 3 data in relapsed/refractory metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Colorectal Neop | 2016 |
Safety of an oral anticancer agent (trifluridine/tipiracil combination tablet) in patients with advanced and recurrent colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Drug Combinations; Female; | 2016 |
A case of secondary malignant giant-cell tumor of bone with p53 mutation after long-term follow-up.
Topics: Adenocarcinoma; Arthrography; Base Sequence; Cell Transformation, Neoplastic; Cysteine; Femur; Fibro | 2011 |
Gene polymorphism of interleukin-1 alpha and beta in keratocystic odontogenic tumors.
Topics: Adolescent; Adult; Aged; Alleles; Case-Control Studies; Child; Cytosine; Epithelial Cells; Female; F | 2012 |
Associations between single-nucleotide polymorphisms of the VEGF gene and long-term prognosis of oral squamous cell carcinoma.
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cytosine; Disease-Free Survival | 2013 |
Microsatellite GTn-repeat polymorphism in the promoter of heme oxygenase-1 gene is an independent predictor of tumor recurrence in male oral squamous cell carcinoma patients.
Topics: Alleles; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Follow-Up Studies; Forecasting; Ge | 2008 |